News | May 07, 2026
Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated
